As our population continues to grow and age, finding proper healthcare solutions will remain a top concern. Overall, Americans during the second half of this decade have spent nearly trillions on healthcare and that number continues to rise. A similar story is occurring in the developing world. As rising incomes and the new middle class crave many of the same "luxuries" as the west, healthcare spending by these nations will also rise. However, while much of investor attention in the sector has gone towards the major pharmaceutical companies or funds like iShares Dow Jones US Pharmaceuticals (NYSE:IHE), that may not be the best choice. With the "Age of the Blockbuster" coming to an end, big pharma must reposition itself. For investors, that could lead to gains.

TUTORIAL: Retirement Planning

Higher R&D Spending
The major pharmaceutical companies are staring down the barrel of gun. Billions of dollars worth of patented, protected drugs are expected to go generic over the next few years. In 2012 alone, more than billions worth of drugs will lose their patents including Singulair, Viagra and the Sanofi-Aventis (NYSE:SNY) and Bristol-Myers Squibb (NYSE:BMY) gigantic success Plavix. However, in the face of this problem, the majors continue to cut costs, specifically in research and development. For example, GlaxoSmithKline (NYSE:GSK) has extensively cut its R&D costs by closing research facilities and doing less discovery work in-house.

The task of drug innovation has fallen to the biotech sector. Overall R&D expenditures for smaller biotech firms as a percentage of revenue are roughly 108%, versus the 54% for larger firms. Some analysts also estimate that by 2014, biotech drugs will account for almost 50% of the top 100 drugs. This compares to just 28% in 2008 and only 11% in 2000. With some biotech treatments for rare diseases costing thousands, big pharma has been taking notice of biotech's potential. Partnerships between the sectors are on the rise, and more recently acquisition activity has picked. Sanofi's purchase of Genzyme was just the tip of the iceberg. More recently, Israel's Teva Pharmaceuticals (Nasdaq:TEVA) agreed to purchase Cephalon (Nasdaq:CEPH) for $6.2 billion. There is a general need for drugs that treat diseases such as diabetes, hepatitis C, and cancer that have high current demand and favorable demographic trends. With the biotech industry focusing on rare diseases and antibodies, will suit it well going forward.

Healthcare Lotto Tickets
Historically, biotech investing has been described like playing the lottery. Generally, companies within the sector are small labs with just one drug under their belts and the vast numbers of them fail. These companies rise and fall with each round of FDA testing. For investors, Betting on a basket of these companies may be best. Both the SPDR S&P Biotech (NYSE:XBI) and iShares Nasdaq Biotechnology (NYSE:IBB) allow investors to add a wide swath of the industry to a portfolio.

For those investors looking to play the lotto aspect of biotech, Aeterna Zentaris (Nasdaq:AEZS) could be a good bet. The company has a rich pipeline of biotech drugs and its colorectal cancer treatment has entered late stage phase 3 trials. Similarly, small biotech Zalicus (Nasdaq:ZLCS) quality drug pipeline has analysts at Oppenheimer upping the company's share price target to $4.

Finally, for those who wish to play the take-over angle, analysts at Morningstar see Biogen (Nasdaq:BIIB), Seattle Genetics (Nasdaq:SGEN) and BioMarin (Nasdaq:BMRN) as possible acquisition targets from big pharma. These firms have strong pipelines as well as variety of rare disease drugs that could supplement the major pharmaceuticals offerings.

The Bottom Line
In the wake of the big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors. As both the primary driver of new drug innovation as well as being a source of growth for the majors, biotech's dominance in healthcare is assured. For investors, adding a fund like the First Trust NYSE Arca Biotech Index (NYSE:FBT) could do portfolio wonders. (One program is for the poor; the other is for the elderly. Learn which is which. See What's The Difference Between Medicare And Medicaid?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Chart Advisor

    Watch This ETF For Signs Of A Reversal (BCX)

    Trying to determine if the commodity markets are ready for a bounce? Take a look at the analysis of this ETF to find out if now is the time to buy.
  2. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  3. Mutual Funds & ETFs

    ETFs Can Be Safe Investments, If Used Correctly

    Learn about how ETFs can be a safe investment option if you know which funds to choose, including the basics of both indexed and leveraged ETFs.
  4. Mutual Funds & ETFs

    The Top 5 Large Cap Core ETFs for 2016 (VUG, SPLV)

    Look out for these five ETFs in 2016, and learn why investors should closely watch how the Federal Reserve moves heading into the new year.
  5. Economics

    India: Why it Might Pay to Be Bullish Right Now

    Many investors are bullish on India for all the right reasons. Does it present an investing opportunity?
  6. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  7. Investing Basics

    Building My Portfolio with BlackRock ETFs and Mutual Funds (ITOT, IXUS)

    Find out how to construct the ideal investment portfolio utilizing BlackRock's tools, resources and its popular low-cost exchange-traded funds (ETFs).
  8. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  9. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  10. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
RELATED FAQS
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center